These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 2260141)
1. Bay U 3405 inhibits cerebral vasospasm induced by authentic thromboxane A2. Braun M; Schrör K Stroke; 1990 Dec; 21(12 Suppl):IV152-4. PubMed ID: 2260141 [TBL] [Abstract][Full Text] [Related]
2. Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease. Fiedler VB; Seuter F; Perzborn E Stroke; 1990 Dec; 21(12 Suppl):IV149-51. PubMed ID: 2260140 [TBL] [Abstract][Full Text] [Related]
3. Effects of the prostaglandin H2/thromboxane A2 antagonist BM 13.177 on human platelets. Patscheke H; Stegmeier K Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():371-3. PubMed ID: 3159225 [No Abstract] [Full Text] [Related]
4. Synthesis and absolute configuration of the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropan oic acid and comparison with its enantiomer. Rosentreter U; Böshagen H; Seuter F; Perzborn E; Fiedler VB Arzneimittelforschung; 1989 Dec; 39(12):1519-21. PubMed ID: 2624597 [TBL] [Abstract][Full Text] [Related]
5. Characterization of Bay U 3405, a novel thromboxane A2/endoperoxide receptor antagonist. Perzborn E; Fiedler VB; Seuter F; Stasch JP; Weber H; Sander E; Böshagen H; Rosentreter U Stroke; 1990 Dec; 21(12 Suppl):IV143-5. PubMed ID: 2148034 [TBL] [Abstract][Full Text] [Related]
6. BAY u3405 an antagonist of thromboxane A2- and prostaglandin D2-induced bronchoconstriction in the guinea-pig. Francis HP; Greenham SJ; Patel UP; Thompson AM; Gardiner PJ Br J Pharmacol; 1991 Nov; 104(3):596-602. PubMed ID: 1797323 [TBL] [Abstract][Full Text] [Related]
7. Influence of trapidil derivatives on arachidonic acid- and prostaglandin endoperoxide analogue- induced platelet aggregation and thromboxane A2 formation. Heinroth I; Block HU; Mest HJ Biomed Biochim Acta; 1984; 43(8-9):S389-92. PubMed ID: 6440555 [TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death. Patscheke H; Stegmeier K; Müller-Beckmann B; Sponer G; Staiger C; Neugebauer G Biomed Biochim Acta; 1984; 43(8-9):S312-8. PubMed ID: 6097235 [TBL] [Abstract][Full Text] [Related]
9. BAY u3405, a potent and selective thromboxane A2 receptor antagonist on airway smooth muscle in vitro. McKenniff MG; Norman P; Cuthbert NJ; Gardiner PJ Br J Pharmacol; 1991 Nov; 104(3):585-90. PubMed ID: 1839139 [TBL] [Abstract][Full Text] [Related]
10. Interference of the thromboxane antagonist SK&F 88046 with platelet activation and subsequent desensitization by arachidonic acid and the thromboxane mimetics U46619 and EP171. Vargaftig B; Joseph D; Hatmi M Thromb Res; 1987 May; 46(4):509-17. PubMed ID: 3039684 [TBL] [Abstract][Full Text] [Related]
11. The effect of naftidrofuryl on PGF2 alpha, U 46.619, 5-HT and thromboxane A2 (TXA2) induced vasoconstriction. Verheggen R; Schrör K Biomed Biochim Acta; 1988; 47(10-11):S264-7. PubMed ID: 3248112 [TBL] [Abstract][Full Text] [Related]
12. The use of synthetic thromboxane A2 (TXA2-S) and a new class of thromboxane antagonists, indole-2-propanoic acids to characterize the thromboxane receptor. Gillard JW; Morton HE; Fortin R; Yoakim C; Girard Y; Lord A; Ethier D; Leveille C; Letts G; Evans J Prog Clin Biol Res; 1989; 301():579-83. PubMed ID: 2529557 [No Abstract] [Full Text] [Related]
13. pH-dependent binding of the TXA2/PGH2-receptor of human platelet membranes to various ligands. Theis JG; Dellweg H; Perzborn E; Gross R Agents Actions Suppl; 1992; 37():222-7. PubMed ID: 1385924 [TBL] [Abstract][Full Text] [Related]
14. Effect of BAY u3405, a thromboxane A2 receptor antagonist, on neuro-effector transmission in canine tracheal tissue. Aizawa H; Takata S; Shigyo M; Matsumoto K; Koto H; Inoue H; Hara N Prostaglandins Leukot Essent Fatty Acids; 1995 Sep; 53(3):213-7. PubMed ID: 7480085 [TBL] [Abstract][Full Text] [Related]
15. Possible generation of potent vasocontracting substance from prostaglandin endoperoxide analogs, human platelets mixture. Shibata S; Ho WK; Ishida U J Pharmacol Exp Ther; 1980 Nov; 215(2):357-62. PubMed ID: 7441499 [TBL] [Abstract][Full Text] [Related]
16. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate. Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331 [TBL] [Abstract][Full Text] [Related]
17. Effect of trimetoquinol analogs for antagonism of endoperoxide/thromboxane A2-mediated responses in human platelets and rat aorta. Mukhopadhyay A; Navran SS; Amin HM; Abdel-Aziz SA; Chang J; Sober DJ; Miller DD; Feller DR J Pharmacol Exp Ther; 1985 Jan; 232(1):1-9. PubMed ID: 3855323 [TBL] [Abstract][Full Text] [Related]
18. Effect of Bay U 3405, a new thromboxane antagonist, on collagen-induced thromboembolism in rabbits. Seuter F; Perzborn E; Fiedler VB Stroke; 1990 Dec; 21(12 Suppl):IV146-8. PubMed ID: 2260139 [TBL] [Abstract][Full Text] [Related]
19. The effect of a thromboxane A2 receptor antagonist BAY-u-3405 on experimental allergic reactions. Nagai H; Takeda H; Yamaguchi S; Tanaka H; Matsuo A; Inagaki N Prostaglandins; 1995 Aug; 50(2):75-87. PubMed ID: 8588075 [TBL] [Abstract][Full Text] [Related]
20. Effect of ridogrel on vascular contractions caused by vasoactive substances released during platelet activation. Janssens WJ; Cools FJ; Hoskens LA; Van Nueten JM Thromb Haemost; 1990 Aug; 64(1):91-6. PubMed ID: 2148850 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]